{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Clearside Biomedical, Inc.
Clearside Biomedical Hits New 52-Week High, Surging 230% in a Year
Clearside Biomedical, Inc. has achieved a new 52-week high, reflecting a significant increase over the past year and outperforming the S&P 500. With a market cap of USD 26 million, the company demonstrates effective management of shareholder equity, despite its loss-making status and complex valuation metrics.
Clearside Biomedical Hits New 52-Week High of $4.52, Up 265.83%
Clearside Biomedical, Inc. has achieved a new 52-week high, reflecting a substantial increase over the past year and significantly outperforming the S&P 500. With a market cap of USD 26 million, the company demonstrates effective management through a high return on equity and a strong balance sheet.
Is Clearside Biomedical, Inc. technically bullish or bearish?
As of August 18, 2025, Clearside Biomedical, Inc. is in a bearish trend with weak strength, indicated by mildly bearish daily moving averages and bearish weekly RSI, despite recent short-term outperformance against the S&P 500.
Is Clearside Biomedical, Inc. overvalued or undervalued?
As of August 14, 2023, Clearside Biomedical, Inc. is rated as risky and overvalued due to negative valuation ratios, despite a recent stock price surge of 1012.70%, indicating that investors should exercise caution.
Clearside Biomedical Hits New 52-Week High of $4.43, Up 229%
Clearside Biomedical, Inc. has achieved a new 52-week high, reflecting a substantial one-year stock performance increase. With a market capitalization of USD 26 million, the company shows a strong return on equity despite being loss-making. Its unique financial structure includes a negative debt-to-equity ratio and price-to-book ratio.
Clearside Biomedical Reports Strong Sales Growth Amid Mixed Financial Indicators in June 2025
Clearside Biomedical, Inc. reported its financial results for the quarter ending June 2025, showcasing significant year-on-year growth in net sales and achieving peak profitability metrics over the last five periods. The company improved its debt-equity ratio, although it faces challenges with reduced cash and equivalents.
Is Clearside Biomedical, Inc. overvalued or undervalued?
As of August 14, 2023, Clearside Biomedical, Inc. is considered risky and overvalued due to its negative financial metrics, including a P/E ratio and price-to-book value that indicate poor performance compared to peers like Kinnate Biopharma and Veru, alongside a significant stock underperformance of -24.04% over the past year.
Is Clearside Biomedical, Inc. technically bullish or bearish?
As of June 20, 2025, Clearside Biomedical, Inc. shows a mildly bearish trend due to mixed technical indicators, with weekly signals slightly bullish but monthly indicators remaining bearish.
Who are in the management team of Clearside Biomedical, Inc.?
As of March 2022, the management team of Clearside Biomedical, Inc. includes Dr. Christy Shaffer as the Independent Chairman and Dr. George Lasezkay as the President and CEO, along with several Independent Directors on the Board.
What does Clearside Biomedical, Inc. do?
Clearside Biomedical, Inc. is a clinical biopharmaceutical company focused on developing innovative therapies for blinding eye diseases. As of March 2025, it reported net sales of $2 million and a net loss of $8 million, with a market cap of $61.39 million.
How big is Clearside Biomedical, Inc.?
As of Jun 18, Clearside Biomedical, Inc. has a market capitalization of 61.39 million, with net sales of 3.77 million and a net profit of -30.81 million over the last four quarters. The company's shareholder's funds are -38.85 million, and total assets are 25.13 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
